Essex Investment Management Co. LLC Buys New Stake in InspireMD, Inc. (NYSE:NSPR)

Essex Investment Management Co. LLC purchased a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 72,565 shares of the company’s stock, valued at approximately $191,000. Essex Investment Management Co. LLC owned approximately 0.28% of InspireMD at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Affiance Financial LLC increased its position in shares of InspireMD by 2.9% during the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after purchasing an additional 5,376 shares in the last quarter. Parkman Healthcare Partners LLC purchased a new position in InspireMD during the 3rd quarter worth approximately $279,000. Finally, Legato Capital Management LLC purchased a new position in InspireMD during the 4th quarter worth approximately $47,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Stock Up 1.1 %

NSPR opened at $2.84 on Monday. InspireMD, Inc. has a 52 week low of $1.81 and a 52 week high of $3.80. The business has a 50 day moving average price of $2.84 and a two-hundred day moving average price of $2.76. The company has a market cap of $74.08 million, a PE ratio of -3.79 and a beta of 0.88.

Analyst Upgrades and Downgrades

NSPR has been the subject of several research analyst reports. StockNews.com began coverage on InspireMD in a report on Monday. They issued a “sell” rating for the company. Lake Street Capital started coverage on shares of InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective on the stock.

InspireMD Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.